Vyne Therapeutics
VYNEVYNE · Stock Price
Historical price data
Overview
VYNE Therapeutics is a clinical-stage biopharma company with a mission to solve difficult therapeutic challenges by questioning traditional assumptions. Its core asset is the InhiBET™ platform for developing topical and oral BET inhibitors, with lead candidate VYN201 in Phase 1b for vitiligo. The company's near-term future is defined by a pending all-stock merger with Yarrow Bioscience, announced in December 2025, which will bring a new lead program (YB-101 for Graves' disease) and approximately $200 million in capital, aiming to create a new entity focused on autoimmune endocrinology.
Technology Platform
The InhiBET™ platform develops topical and oral small-molecule inhibitors of BET proteins, epigenetic regulators of inflammatory and fibrotic gene expression, aiming for targeted therapy with improved safety profiles.
Pipeline
36| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Isotretinoin + Amzeeq 4% Topical Foam | Acne Vulgaris | Approved | |
| FMX103 minocycline foam 1.5% + Vehicle foam | Facial Papulopustular Rosacea | Phase 3 | |
| 5 mg Serlopitant Tablets | Pruritus | Phase 3 | |
| 5mg Serlopitant Tablets + Placebo Tablets | Pruritus | Phase 3 | |
| FMX-101, 4% minocycline foam + Vehicle Foam | Acne Vulgaris | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
VYN201 faces competition from approved topical JAK inhibitors in vitiligo. YB-101 will compete with teprotumumab in TED and other biologics, with its differentiation resting on its first-in-class TSHR target. Success requires demonstrating clear clinical superiority or a better safety profile.
